Apixaban Dosing for Deep Vein Thrombosis Treatment

Dosing Schedule

• The American College of Chest Physicians recommends an initial treatment phase of 10 mg orally twice daily for 7 days, followed by a maintenance phase of 5 mg orally twice daily for at least 3 months, as demonstrated in the Chest journal 1

Evidence Supporting This Regimen

• The AMPLIFY trial showed that apixaban (10 mg twice daily for 7 days followed by 5 mg twice daily for 6 months) was non-inferior to conventional therapy in preventing recurrent VTE or VTE-related death, with a lower incidence of major bleeding (0.6% vs 1.8%) 2, 1

Special Considerations

Renal Function

• The National Comprehensive Cancer Network recommends avoiding apixaban in patients with severe renal impairment (CrCl <15 mL/min) and excluding patients with CrCl <25 mL/min from clinical trials 3

Monitoring

• Routine laboratory monitoring is not required for apixaban, as the fixed-dose regimen provides predictable anticoagulation without the need for regular blood tests, according to the Chest journal 1